1.Thomas ED，Lochte HL，Jr.，Lu WC，Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. New Eng J Med，1957，257（11）：491-496.

2.周光炎.免疫学原理.第4版.北京：科学出版社，2018.

3.黄晓军.实用造血干细胞移植.北京：人民卫生出版社，2014.

4.Cooper MA，Fehniger TA，Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol，2001，22（11）：633-640.

5.Zhao XY，Chang YJ，Huang XJ. Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation：do the reconstitution kinetics of natural killer cells create these differences？ Biol Blood Marrow Transplant，2011，17（10）：1436-1442.

6.Ciurea SO，Cao K，Fernadez-Vina M，et al. The European Society for Blood and Marrow Transplantation （EBMT）Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies （DSA） in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant，2018，53（5）：521-534.

7.Ferrara JLM，Levine JE，Reddy P，Holler E. Graft-versus-host disease. Lancet，2009，373（9674）：1550-1561.

8.Zeiser R，Blazar BR. Acute Graft-versus-Host Disease - Biologic Process，Prevention，and Therapy. N Engl J Med，2017，377（22）：2167-2179.

9.Zeiser R，Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med，2017，377（26）：2565-2579.